Effect of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 6, 2011, Pages 1797-1804

  Ahmed, Ashraf H ^a   Gordon, Richard D ^a   Taylor, Paul J ^a   Ward, Gregory ^b   Pimenta, Eduardo ^a   Stowasser, Michael ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b SULLIVAN NICOLAIDES PATHOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CREATININE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETONOGESTREL; HYDROCORTISONE; POTASSIUM; RENIN; SODIUM;

ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RENIN RATIO; ALDOSTERONE URINE LEVEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; FALSE POSITIVE RESULT; FEMALE; HUMAN; HYDROCORTISONE URINE LEVEL; MEDICAL PARAMETERS; NORMAL HUMAN; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; POTASSIUM URINE LEVEL; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SCREENING; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL;

ADULT; ALDOSTERONE; ANDROSTENES; BLOOD PRESSURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYDROCORTISONE; IMMUNOASSAY; LUTEINIZING HORMONE; PROGESTERONE; RENIN; REPRODUCTIVE CONTROL AGENTS; TANDEM MASS SPECTROMETRY;

EID: 79956313260     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-2918     Document Type: Article

References (40)

1. Stowasser M, Gordon RD 2003 Primary aldosteronism. Best Pract Res Clin Endocrinol Metab 17:591-605
2. Kaplan NM 1969 Commentary on incidence of primary aldosteronism: current estimations based on objective data. Arch Intern Med 123:152-154
3. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC 1994 High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 21:315-318 (Pubitemid 24201225)
4. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM 2000 High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 14:311-315 (Pubitemid 30311512)
5. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young Jr WF 2000 Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 85:2854-2859 (Pubitemid 32269163)
6. Nishikawa T, Saito J, Omura M 2007 Is primary aldosteronism rare or common among hypertensive patients? Hypertens Res 30:103-104
7. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F 2006 A Prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48:2293-2300 (Pubitemid 44873058)
8. Young Jr WF 1999 Primary aldosteronism: a common and curable form of hypertension. Cardiol Rev 7:207-214
9. Ahmed AH, Gordon RD, Taylor P, Ward G, Pimenta E, Stowasser M 2010 Effect of atenolol on aldosterone/renin ratio calculated by both plasma renin activity and direct renin concentration in healthy male volunteers. J Clin Endocrinol Metab 95:3201-3206
10. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F 2002 Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 40:897-902 (Pubitemid 35434913)
11. Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J 2002 Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol (Oxf) 57:457-465 (Pubitemid 35221345)
12. Fiad TM, Cunningham SK, Hayes FJ, McKenna TJ 1997 Effects of nifedipine treatment on the renin-angiotensin-aldosterone axis. J Clin Endocrinol Metab 82:457-460 (Pubitemid 27068611)
13. Mitnick PD, Greenberg A, DeOreo PB, Weiner BM, Coffman TM, Walker BR, Agus ZS, Goldfarb S 1980 Effects of two nonsteroidal anti-inflammatory drugs, indomethacin and oxaprozin, on the kidney. Clin Pharmacol Ther 28:680-689 (Pubitemid 11254170)
14. Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ 2001 Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2:156-169 (Pubitemid 33685887)
15. Stowasser M, Gordon RD 2004 The aldosterone-renin ratio in screening for primary aldosteronism. Endocrinologist 14:267-276 (Pubitemid 39232121)
16. McKenna TJ, Sequeira SJ, Heffernan A, Chambers J, Cunningham S 1991 Diagnosis under random conditions of all disorders of the renin-angiotensin- aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 73:952-957
17. Gordon RD 1995 Primary aldosteronism. J Endocrinol Invest 18:495-511
18. Gordon RD, Wolfe LK, Island DP, Liddle GW 1966 A diurnal rhythm in plasma renin activity in man. J Clin Invest 45:1587-1592
19. Gordon MS, Chin WW, Shupnik MA 1992 Regulation of angiotensinogen gene expression by estrogen. J Hypertens 10:361-366
20. Oelkers WK 1996 Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 61:166-171 (Pubitemid 26146736)
21. Sitruk-Ware R 2008 Pharmacological profile of progestins. Maturitas 61:151-157
22. Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A 2003 Conception and pharmacodynamic profile of drospirenone. Steroids 68:891-905 (Pubitemid 37532413)
23. Oelkers W, Schöneshöfer M, Blümel A 1974 Effects of progesterone and four synthetic progestagens on sodium balance and the renin-aldosterone system in man. J Clin Endocrinol Metab 39:882-890
24. Crane MG, Harris JJ 1969 Plasma renin activity and aldosterone excretion rate in normal subjects. II. Effect of oral contraceptive agents. J Clin Endocrinol Metab 29:558-562
25. Katz FH, Beck P 1974 Plasma renin activity, renin substrate and aldosterone during treatment with various oral contraceptives. J Clin Endocrinol Metab 39:1001-1004
26. Gordon RD 2004 The challenge of more robust and reproducible methodology in screening for primary aldosteronism. J Hypertens 22:251-255 (Pubitemid 38250981)
27. Schirpenbach C, Seiler L, Maser-Gluth C, Beuschlein F, Reincke M, Bidlingmaier M 2006 Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clin Chem 52:1749-1755 (Pubitemid 44330710)
28. Taylor PJ, Cooper DP, Gordon RD, Stowasser M 2009 Measurement of Aldosterone in Human Plasma by Semiautomated HPLC-Tandem Mass Spectrometry. Clin Chem 55:1155-1162
29. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM 2008 Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:3266-3281
30. Ahmed AH, Gordon RD, Taylor PJ, Ward G, Pimenta E, Stowasser M 2011 Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men? J Clin Endocrinol Metab 96:E340-E346
31. Adams K, Beal MW 2009 Implanon: a review of the literature with recommendations for clinical management. J Midwifery Womens Health 54:142-149
32. Mishell Jr DR 2008 YAZ and the novel progestin drospirenone. J Reprod Med 53:721-728
33. Meulenberg PM, Ross HA, Swinkels LM, Benraad TJ 1987 The effect of oral contraceptives on plasma-free and salivary cortisol and cortisone. Clin Chim Acta 165:379-385 (Pubitemid 17113696)
34. Sandberg AA, Woodruff M, Rosenthal H, Nienhouse S, Slaunwhite Jr WR 1964 Transcortin: a corticosteroid-binding protein of plasma. VII. Half-life in normal and estrogen-treated subjects. J Clin Invest 43:461-466
35. Pizzolo F, Pavan C, Corrocher R, Olivieri O 2007 Laboratory diagnosis of primary aldosteronism, and drospirenone-ethinylestradiol therapy. Am J Hypertens 20:1334-1337 (Pubitemid 350151688)
36. Pizzolo F, Raffaelli R, Memmo A, Chiecchi L, Pavan C, Guarini P, Guidi GC, Franchi M, Corrocher R, Olivieri O 2010 Effects of female sex hormones and contraceptive pill on the diagnostic work-up for primary aldosteronism. J Hypertens 28:135-142
37. Losert W, Casals-Stenzel J, Buse M 1985 Progestogens with anti-mineralocorticoid activity. Arzneimittelforschung 35:459-471
38. Biswas A, Biswas S, Viegas OA 2004 Effect of etonogestrel subdermal contraceptive implant (Implanon) on liver function tests: a randomized comparative study with Norplant implants. Contraception 70:379-382 (Pubitemid 39422514)
39. Croxatto HB, Mäkäräinen L 1998 The pharmacodynamics and efficacy of Implanon: an overview of the data. Contraception 58:91S-97S
40. Mäkäräinen L, van Beek A, Tuomivaara L, Asplund B, Coelingh Bennink H 1998 Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril 69:714-721 (Pubitemid 28188469)